Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

www.semaspace.com

Has www.semaspace.com received an FDA warning letter? Yes. FDA issued a warning letter dated October 2, 2023 concerning products containing semaglutide.

Letter facts

Letter date
October 2, 2023 (2023-10-02)
Issuing office
Center for Drug Evaluation and Research | CDER
Recipient type
Manufacturer / API
Products named
Semaglutide 2mgSemaglutide 5mgGeneric semaglutide 2mg vialGeneric semaglutide 5mg vial
Violation categories
Unapproved new drugMisbranding

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Factual Violation Summary

FDA says the website offered unapproved, misbranded injectable semaglutide 2mg and 5mg products to U.S. consumers without FDA approval, adequate directions for use, or a prescription, violating FD&C Act sections 301(a), 301(d), 301(k), 503(b), and 505(a).

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • unapproved new drugs
  • misbranded drugs
  • labeling lacking adequate directions for use
  • dispensing prescription drugs without a prescription

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.